ZyVersa Therapeutics' CEO, Stephen C. Glover, Is an Invited Speaker at H.C.

ZyVersa is advancing a dynamic pipeline of drug candidates with multiple programs built around two proprietary technologies – Phase 2a Cholesterol Efflux Mediator™ VAR 200 for treatment of kidney diseases, and Inflammasome ASC Inhibitor IC 100 for treatment of obesity and its associated metabolic complications, among other inflammatory diseases. Mr. Glover welcomes one-on-one meetings with registered participants. Details regarding Mr. Glover's Presentation follow: About ZyVersa Therapeutics, Inc. WESTON, F ...